A genetic defect in 5, 10 methylenetetrahydrofolate reductase in neural tube defects

QJM

Volumn 88, Issue 11, 1995, Pages 763-766

  Whitehead, A S ^a   Gallagher, P ^a   Mills, J L ^b   Kirke, P N ^c   Burke, H ^c   Molloy, A M ^d   Weir, D G ^d   Shields, D C ^a   Scott, J M ^e  

^a Biotechnology Institute ^*  (Ireland)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c HEALTH RESEARCH BOARD   (Ireland)

^d Department of Clinical Medicine ^*  (Ireland)

^e TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA; FOLIC ACID; HOMOCYSTEINE;

ALLELE; AMINO ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DNA DETERMINATION; GENETIC DISORDER; GENETIC SCREENING; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NEURAL TUBE DEFECT; PRIORITY JOURNAL;

AMINE OXIDOREDUCTASES; CASE-CONTROL STUDIES; GENOTYPE; HUMAN; NEURAL TUBE DEFECTS; ODDS RATIO; SUPPORT, NON-U.S. GOV'T;

EID: 0028803474     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/oxfordjournals.qjmed.a069003     Document Type: Article

References (11)

1. MRC Vitamin Study Research Croup. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-7
2. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Englj Med 1992; 327:1832-5
3. 12are independent risk factors for neural tube defects. Q J Med 1993; 86:703-8
4. Mills JL, Tuomilehto J, Yu KF, Colman N, Blaner WS, Koskela P, Rundle WE, Forman M, Toivanen L, Rhoads CC, Maternal vitamin levels during pregnancies producing infants with neural tube defects. J Pediatr 1992; 120:863-71
5. 2concentrations in pregnancies associated with neural tube defects. Arch Dis Child 1985; 60:660-5
6. Steegers-Theunissen R, Boers C, Trijbels FJ, Eskes TK. Neural-tube defects and derangement of homocysteine metabolism. N Engl j Med 1991; 324:199-200 [letter]
7. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DC, Scott JM. Homocysteine metabolism in pregnancies complicated by neural tube defects. Lancet 1995; 345:149-51
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RC, Boers CJH, den Heizer M, Kluijtmans LAJ, van den Henvel LP and Rosen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10:111-13
9. Scott JM, Kirke PN, Weir DG. Folate and neural tube defects. CIBA Symposium 181. London, John Wiley and Sons, 1994
10. CDC. Prevention program for reducing risk for neural tube defects—South Carolina, 1992-1994. MMWR 1995; 44:141-2
11. Clark, NAC, Fisk NM. Minimal compliance with the Department of Health recommendation for routine folate prophylaxis to prevent foetal neural tube defects. Br J Obstet Gynaecol 1994; 101:709-10